Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01942850 · ClinicalTrials.gov registry record
International Ataxia Rating Scale in Younger Patients
A clinical trial, sponsored by Quince Therapeutics S.p.A..
- Completed
- Registry status
- 63
- Enrollment target
NCT01942850: Completed study, sponsored by Quince Therapeutics S.p.A..
NCT01942850 is a clinical trial that has completed, run by Quince Therapeutics S.p.A.. The registered enrollment target is 63 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01942850 has completed, sponsored by Quince Therapeutics S.p.A..
- COMPLETED
- Registry status
- 63 participants
- Enrollment target
Study Summary
The project will collect information on the mapping of clinical ratings on a number of scales that are used in the assessment of patients with ataxias.
Primary Outcome
The primary outcome is validity of ICARS in children younger than 10 years of age (by comparing the mean scores and subscores between children aged 6-10 years of age to those aged 10-18 years of age).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-05 |
What the finished NCT01942850 record still lists
NCT01942850 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 63 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01942850 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01942850 about?
NCT01942850 is a clinical study titled "International Ataxia Rating Scale in Younger Patients". The project will collect information on the mapping of clinical ratings on a number of scales that are used in the assessment of patients with ataxias.
What is the current status of trial NCT01942850?
This trial is currently completed. The enrollment target is 63 participants. The study started on 2013-08. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT01942850?
This trial is sponsored by Quince Therapeutics S.p.A., which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia